Deep Learning for MRI Segmentation and Molecular Subtyping in Glioblastoma: Critical Aspects from an Emerging Field
-
Published:2024-08-16
Issue:8
Volume:12
Page:1878
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
Bonada Marta12, Rossi Luca Francesco3ORCID, Carone Giovanni2, Panico Flavio1ORCID, Cofano Fabio1, Fiaschi Pietro45, Garbossa Diego1ORCID, Di Meco Francesco2ORCID, Bianconi Andrea14ORCID
Affiliation:
1. Neurosurgery Unit, Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy 2. Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milan, Italy 3. Department of Informatics, Polytechnic University of Turin, Corso Castelfidardo 39, 10129 Turin, Italy 4. Division of Neurosurgery, Ospedale Policlinico San Martino, IRCCS for Oncology and Neurosciences, Largo Rosanna Benzi 10, 16132 Genoa, Italy 5. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health, University of Genoa, Largo Rosanna Benzi 10, 16132 Genoa, Italy
Abstract
Deep learning (DL) has been applied to glioblastoma (GBM) magnetic resonance imaging (MRI) assessment for tumor segmentation and inference of molecular, diagnostic, and prognostic information. We comprehensively overviewed the currently available DL applications, critically examining the limitations that hinder their broader adoption in clinical practice and molecular research. Technical limitations to the routine application of DL include the qualitative heterogeneity of MRI, related to different machinery and protocols, and the absence of informative sequences, possibly compensated by artificial image synthesis. Moreover, taking advantage from the available benchmarks of MRI, algorithms should be trained on large amounts of data. Additionally, the segmentation of postoperative imaging should be further addressed to limit the inaccuracies previously observed for this task. Indeed, molecular information has been promisingly integrated in the most recent DL tools, providing useful prognostic and therapeutic information. Finally, ethical concerns should be carefully addressed and standardized to allow for data protection. DL has provided reliable results for GBM assessment concerning MRI analysis and segmentation, but the routine clinical application is still limited. The current limitations could be prospectively addressed, giving particular attention to data collection, introducing new technical advancements, and carefully regulating ethical issues.
Reference103 articles.
1. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014;Ostrom;Neuro-Oncology,2017 2. Martucci, M., Russo, R., Giordano, C., Schiarelli, C., D’apolito, G., Tuzza, L., Lisi, F., Ferrara, G., Schimperna, F., and Vassalli, S. (2023). Advanced Magnetic Resonance Imaging in the Evaluation of Treated Glioblastoma: A Pictorial Essay. Cancers, 15. 3. Bianconi, A., Palmieri, G., Aruta, G., Monticelli, M., Zeppa, P., Tartara, F., Melcarne, A., Garbossa, D., and Cofano, F. (2023). Updates in Glioblastoma Immunotherapy: An Overview of the Current Clinical and Translational Scenario. Biomedicines, 11. 4. Morello, A., Bianconi, A., Rizzo, F., Bellomo, J., Meyer, A.C., Garbossa, D., Regli, L., and Cofano, F. (2024). Laser Interstitial Thermotherapy (LITT) in Recurrent Glioblastoma: What Window of Opportunity for This Treatment?. Technol. Cancer Res. Treat., 23. 5. Li, R., Ye, J., Huang, Y., Jin, W., Xu, P., and Guo, L. (2024). A continuous learning approach to brain tumor segmentation: Integrating multi-scale spatial distillation and pseudo-labeling strategies. Front. Oncol., 13.
|
|